Targeted radionuclide detection of malignant tumors using affibody

Cover Page

Cite item

Full Text

Abstract

This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.

About the authors

Olga D. Bragina

Tomsk Cancer Research Institute; National Research Tomsk Polytechnic University

Email: rungis@mail.ru
ORCID iD: 0000-0001-5281-7758
SPIN-code: 7961-5918
Scopus Author ID: 57190936256
ResearcherId: E-9732-2017
Russian Federation, Tomsk, 634009; Tomsk, 634050

Alexander A. Nesynov

Tomsk Cancer Research Institute

Author for correspondence.
Email: nesynov.alex@mail.ru
ORCID iD: 0009-0000-1661-7396
Russian Federation, Tomsk, 634009

Ekaterina Yu. Sitnikova

Siberian State Medical University

Email: sitnikova_katerina00@mail.ru
Russian Federation, Tomsk, 634050

Stanislav V. Patalyak

Tomsk Cancer Research Institute; Siberian State Medical University

Email: patalyak@gmail.com
ORCID iD: 0000-0002-9468-1980
SPIN-code: 8497-1750
Scopus Author ID: 56324415300
ResearcherId: D-2358-2012
Russian Federation, Tomsk, 634009; Tomsk, 634050

Sergey M. Deyev

National Research Tomsk Polytechnic University; Shemyakin-Ovchinnikov Institute of Biorganic Chemistry of the Russian Academy of Sciences

Email: biomem@mail.ru
ORCID iD: 0000-0002-3952-0631
SPIN-code: 2562-1845
Scopus Author ID: 6603799895
ResearcherId: F-8191-2014
Russian Federation, Tomsk, 634050; Moscow, 117997

References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
  2. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Zlokachestvennye novoobrazovaniia v Rossii v 2023 godu (zabolevaemost i smertnost) [Malignant neoplasms in Russia in 2023 (morbidity and mortality)]. P.A. Gertsen Moscow Oncology Research Institute; 2024.
  3. Cai A, Chen Y, Wang LS, Cusick JK, Shi Y. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer. Cancers (Basel). 2024;16(15):2635. doi: 10.3390/cancers16152635
  4. Cai M, Song XL, Li XA, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962. doi: 10.1016/j.drup.2023.100962
  5. Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66. doi: 10.1186/s12943-024-01967-3
  6. Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041
  7. Chae KJ, Hong H, Yoon SH, et al. Non-diagnostic Results of Percutaneous Transthoracic Needle Biopsy: A Meta-analysis. Sci Rep. 2019;9(1):12428. doi: 10.1038/s41598-019-48805-x
  8. Laurent F, Montaudon M, Latrabe V, Bégueret H. Percutaneous biopsy in lung cancer. Eur J Radiol. 2003;45(1):60-68. doi: 10.1016/s0720-048x(02)00286-3
  9. Kemeny MM, Busch-Devereaux E, Merriam LT, O’Hea BJ. Cancer surgery in the elderly. Hematol Oncol Clin North Am. 2000;14(1):169-192. doi: 10.1016/s0889-8588(05)70283-5
  10. Nicolò E, Serafini MS, Munoz-Arcos L, et al. Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications. J Liq Biopsy. 2023;2:100117. doi: 10.1016/j.jlb.2023.100117
  11. Hou Y, Nitta H, Li Z. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers (Basel). 2023;15(10):2664. doi: 10.3390/cancers15102664
  12. Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. doi: 10.1016/j.ctrv.2021.102286
  13. Laprovitera N, Riefolo M, Ambrosini E, Klec C, Pichler M, Ferracin M. Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers (Basel). 2021;13(3):451. doi: 10.3390/cancers13030451
  14. Harms PW, Frankel TL, Moutafi M, et al. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists. Mod Pathol. 2023;36(7):100197. doi: 10.1016/j.modpat.2023.100197
  15. Lino-Silva LS, Gamboa-Domínguez A, Zúñiga-Tamayo D, López-Correa P. Interobserver variability in colorectal cancer and the 2016 ITBCC concensus. Mod Pathol. 2019;32(1):159-160. doi: 10.1038/s41379-018-0027-5
  16. Wu Q, Xu L. Challenges in HER2-low breast cancer identification, detection, and treatment. Transl Breast Cancer Res. 2024;5:3. doi: 10.21037/tbcr-23-48
  17. Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The Future of Precision Oncology. Int J Mol Sci. 2023;24(16):12613. doi: 10.3390/ijms241612613
  18. Langbein T, Weber WA, Eiber M. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019;60(S2):13S-19S. doi: 10.2967/jnumed.118.220566
  19. Idée JM, Louguet S, Ballet S, Corot C. Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med Surg. 2013;3(6):292-297. doi: 10.3978/j.issn.2223-4292.2013.12.06
  20. Klain M, Nappi C, Zampella E, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4437-4444. doi: 10.1007/s00259-021-05440-x
  21. Bauckneht M, Ciccarese C, Laudicella R, et al. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives. Cancer Treat Rev. 2024;124:102698. doi: 10.1016/j.ctrv.2024.102698
  22. Kasi PB, Mallela VR, Ambrozkiewicz F, Trailin A, Liška V, Hemminki K. Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances. Int J Mol Sci. 2023;24(9):7922. doi: 10.3390/ijms24097922
  23. Song Y, Zou J, Castellanos EA, et al. Theranostics − a sure cure for cancer after 100 years? Theranostics. 2024;14(6):2464-2488. doi: 10.7150/thno.96675
  24. Burkett BJ, Bartlett DJ, McGarrah PW, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023;5(4):e220157. doi: 10.1148/rycan.220157
  25. Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534-550. doi: 10.1038/s41571-022-00652-y
  26. Wei Z, Li B, Wen X, et al. Engineered Antibodies as Cancer Radiotheranostics. Adv Sci (Weinh). 2024;11(30):e2402361. doi: 10.1002/advs.202402361
  27. Bragina OD, Chernov VI, Garbukov EYu, et al. Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. Bull Sib Med. 2021;20(1):23-30. doi: 10.20538/1682-0363-2021-1-23-30
  28. Tolmachev V, Vorobyeva A. Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development. Cancers (Basel). 2022;14(2):297. doi: 10.3390/cancers14020297
  29. Bragina OD, Deyev SM, Chernov VI, Tolmachev VM. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. Acta Naturae. 2022;14(2):4-15. doi: 10.32607/actanaturae.11611
  30. Luo R, Liu H, Cheng Z. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy. RSC Chem Biol. 2022;3(7):830-847. doi: 10.1039/d2cb00094f
  31. Tolmachev V, Orlova A, Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin Cancer Biol. 2021;72:185-197. doi: 10.1016/j.semcancer.2020.10.005
  32. Shipunova VO, Deyev SM. Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo. Acta Naturae. 2022;14(1):54-72. doi: 10.32607/actanaturae.11545
  33. Liu J, Cui D, Jiang Y, et al. Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein. Int J Biol Macromol. 2021;166:884-892. doi: 10.1016/j.ijbiomac.2020.10.245
  34. Zhu J, Kamara S, Cen D, et al. Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells. Cell Death Dis. 2020;11(6):494. doi: 10.1038/s41419-020-2692-9
  35. Liu S, Gao C, Tong Z, et al. A highly sensitive electrochemiluminescence method for abrin detection by a portable biosensor based on a screen-printed electrode with a phage display affibody as specific labeled probe. Anal Bioanal Chem. 2022;414(2):1095-1104. doi: 10.1007/s00216-021-03735-4
  36. Barozzi A, Lavoie RA, Day KN, Prodromou R, Menegatti S. Affibody-Binding Ligands. Int J Mol Sci. 2020;21(11):3769. doi: 10.3390/ijms21113769
  37. DiRusso CJ, Dashtiahangar M, Gilmore TD. Scaffold proteins as dynamic integrators of biological processes. J Biol Chem. 2022;298(12):102628. doi: 10.1016/j.jbc.2022.102628
  38. Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017;35(8):691-712. doi: 10.1016/j.tibtech.2017.04.007
  39. Hersh J, Yang YP, Roberts E, et al. Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody-Gaussia Luciferase Fusion Protein. Pharmaceutics. 2023;15(7):1976. doi: 10.3390/pharmaceutics15071976
  40. Du W, Jiang P, Li Q, et al. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants. Microbiol Spectr. 2023;11(1):e0356222. doi: 10.1128/spectrum.03562-22
  41. Gabriele F, Palerma M, Ippoliti R, Angelucci F, Pitari G, Ardini M. Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy. Int J Mol Sci. 2023;24(10):8680. doi: 10.3390/ijms24108680
  42. Cai W, Lv W, Meng L, Duan Y, Zhang L. The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer. Int J Nanomedicine. 2023;18:339-351. doi: 10.2147/IJN.S387409
  43. Wu Y, Li H, Yan Y, et al. Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer. Int J Nanomedicine. 2020;15:4691-4703. doi: 10.2147/IJN.S244172
  44. Zhou H, Liu H, Zhang Y, et al. “PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody”: Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells. Drug Des Devel Ther. 2022;16:1515-1530. doi: 10.2147/DDDT.S351623
  45. Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa. BioDrugs. 2025;39(1):53-74. doi: 10.1007/s40259-024-00687-w
  46. Kerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760-774. doi: 10.1136/ard-2024-225534
  47. Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K. Prostate Cancer Theranostics With 177Lu-PSMA. Semin Nucl Med. 2024;54(4):581-590. doi: 10.1053/j.semnuclmed.2024.02.007
  48. Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules. 2022;27(16):5231. doi: 10.3390/molecules27165231
  49. Zhang L, Zhang H. Recent advances of affibody molecules in biomedical applications. Bioorg Med Chem. 2024;113:117923. doi: 10.1016/j.bmc.2024.117923
  50. Rouanne M, Radulescu C, Adam J, Allory Y. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol. 2021;39(5):1345-1355. doi: 10.1007/s00345-020-03498-0
  51. Mucileanu A, Chira R, Mircea PA. PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Med Pharm Rep. 2021;94(4):402-410. doi: 10.15386/mpr-2116
  52. Lin KX, Istl AC, Quan D, Skaro A, Tang E, Zheng X. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol Immunother. 2023;72(12):3875-3893. doi: 10.1007/s00262-023-03520-5
  53. Liang Z, Hu X, Hu H, Wang P, Cai J. Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Front Oncol. 2022;12:1017737. doi: 10.3389/fonc.2022.1017737
  54. Zhao B, Li H, Xia Y, et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153. doi: 10.1186/s13045-022-01364-7
  55. Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43. doi: 10.1186/s12943-023-01751-9
  56. Oroujeni M, Bezverkhniaia EA, Xu T, et al. Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3. Pharmaceutics. 2022;14(9):1780. doi: 10.3390/pharmaceutics14091780
  57. Oroujeni M, Bezverkhniaia EA, Xu T, et al. Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3. Nucl Med Biol. 2023;124-125:108384. doi: 10.1016/j.nucmedbio.2023.108384
  58. Cai H, Li Z, Shi Q, et al. Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023;50(10):2952-2961. doi: 10.1007/s00259-023-06260-x
  59. Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75-88. doi: 10.1016/j.mam.2017.11.007
  60. Ivanova M, Porta FM, D’Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2024;484(1):3-14. doi: 10.1007/s00428-023-03656-w
  61. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872. doi: 10.1200/JCO.22.02864
  62. Giugliano F, Carnevale Schianca A, Corti C, et al. Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. Cancers (Basel). 2023;15(5):1385. doi: 10.3390/cancers15051385
  63. Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. doi: 10.1093/jnci/djx273
  64. Han J, Chen Y, Zhao Y, et al. Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer. Front Med (Lausanne). 2022;9:803005. doi: 10.3389/fmed.2022.803005
  65. Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31(1):18-23. doi: 10.1097/GCO.0000000000000515
  66. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. PLoS One. 2018;13(1):e0191972. doi: 10.1371/journal.pone.0191972
  67. Murciano-Goroff YR, Suehnholz SP, Drilon A, Chakravarty D. Precision Oncology: 2023 in Review. Cancer Discov. 2023;13(12):2525-2531. doi: 10.1158/2159-8290.CD-23-1194
  68. Hu X, Hu H, Li D, Wang P, Cai J. Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts. Open Med (Wars). 2024;19(1):20241027. doi: 10.1515/med-2024-1027
  69. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101-126. doi: 10.1038/s41573-022-00579-0
  70. Dowling GP, Keelan S, Toomey S, Daly GR, Hennessy BT, Hill ADK. Review of the status of neoadjuvant therapy in HER2-positive breast cancer. Front Oncol. 2023;13:1066007. doi: 10.3389/fonc.2023.1066007
  71. Zimmerman BS, Esteva FJ. Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. Cancers (Basel). 2024;16(4):800. doi: 10.3390/cancers16040800
  72. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51(6):892-897. doi: 10.2967/jnumed.109.073239
  73. Sörensen J, Sandberg D, Sandström M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55(5):730-735. doi: 10.2967/jnumed.113.131243
  74. Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016;6(2):262-271. doi: 10.7150/thno.13502
  75. Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol. 2022;12:894767. doi: 10.3389/fonc.2022.894767
  76. Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. J Nucl Med. 2023;64(9):1364-1370. doi: 10.2967/jnumed.122.265364
  77. Altena R, Burén SA, Blomgren A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study. J Nucl Med. 2024;65(5):700-707. doi: 10.2967/jnumed.123.266847
  78. Bragina O, Chernov V, Larkina M, et al. Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13(14):4858-4871. doi: 10.7150/thno.86770

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bragina O.D., Nesynov A.A., Sitnikova E.Y., Patalyak S.V., Deyev S.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».